Michael R. Folkert, MD, PhD, discusses real-world outcomes with spacer in prostate cancer ...

Panelists discuss how future trials in metastatic castration-resistant prostate cancer (mCRPC) should focus on developing reliable biomarker-driven treatment selection strategies to optimize ...

SunRISe-4 evaluates TAR-200 and cetrelimab in muscle-invasive bladder cancer patients ineligible for cisplatin-based chemotherapy, showing promising pathological response rates. Adverse events were ...

Panelists discuss how the phase 3 DORA trial investigates the combination of standard of care darolutamide with radium-223 in patients with metastatic castration-resistant prostate cancer (mCRPC), ...

"For other health care professionals aiming to advocate for equitable changes within their system, it's really important to just start conversations about what you're noticing," says Hailey Frye.

“I think we now have really robust data showing that earlier treatment intensification with combination regimens does lead to improved survival for patients with metastatic hormone-sensitive prostate ...

Where are you using these treatments in your practice, and how do you choose between them for BCG-unresponsive patients? How have these advances changed the timing of radical cystectomy for patients?

Experts briefly discuss 3 new FDA-approved treatments for patients who are unresponsive to bacille Calmette-Guérin (BCG) in the last 5 years—pembrolizumab, nogapendekin alfa inbakicept-pmln, and ...

177Lu-PSMA-617 is now approved for PSMA-positive mCRPC patients post-ARPI therapy, delaying taxane-based chemotherapy. The phase 3 PSMAfore trial showed a 59% reduction in radiographic progression or ...

The Visby Medical test is the first at-home, prescription-free diagnostic for chlamydia, gonorrhea, and trichomoniasis. It provides results in approximately 30 minutes using a self-collected vaginal ...

"In a practice like mine, where approximately 30% of the practice is low testosterone, it'll have actually very little negative effect," says John P. Mulhall, MD. Following the FDA’s class-wide ...

The FDA approved neoadjuvant durvalumab with gemcitabine and cisplatin, followed by adjuvant durvalumab, for muscle invasive bladder cancer (MIBC). Phase 3 NIAGARA trial results showed improved ...